EP4103208A4 - Recombinant therapeutic interventions for cancer - Google Patents

Recombinant therapeutic interventions for cancer Download PDF

Info

Publication number
EP4103208A4
EP4103208A4 EP21754580.5A EP21754580A EP4103208A4 EP 4103208 A4 EP4103208 A4 EP 4103208A4 EP 21754580 A EP21754580 A EP 21754580A EP 4103208 A4 EP4103208 A4 EP 4103208A4
Authority
EP
European Patent Office
Prior art keywords
cancer
therapeutic interventions
recombinant therapeutic
recombinant
interventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21754580.5A
Other languages
German (de)
French (fr)
Other versions
EP4103208A1 (en
Inventor
William R. Bishai
Trinity J. BIVALACQUA
Alok Singh
Monali PRAHARAJ
Takahiro Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4103208A1 publication Critical patent/EP4103208A1/en
Publication of EP4103208A4 publication Critical patent/EP4103208A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21754580.5A 2020-02-13 2021-02-12 Recombinant therapeutic interventions for cancer Pending EP4103208A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202016790161A 2020-02-13 2020-02-13
PCT/US2021/018007 WO2021163602A1 (en) 2020-02-13 2021-02-12 Recombinant therapeutic interventions for cancer

Publications (2)

Publication Number Publication Date
EP4103208A1 EP4103208A1 (en) 2022-12-21
EP4103208A4 true EP4103208A4 (en) 2024-05-08

Family

ID=77292873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21754580.5A Pending EP4103208A4 (en) 2020-02-13 2021-02-12 Recombinant therapeutic interventions for cancer

Country Status (6)

Country Link
EP (1) EP4103208A4 (en)
JP (1) JP2023514553A (en)
CN (1) CN115443143A (en)
AU (1) AU2021220986A1 (en)
CA (1) CA3167223A1 (en)
WO (1) WO2021163602A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014391A1 (en) * 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019203965A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
SG11201906161VA (en) * 2017-01-06 2019-08-27 Synlogic Operating Co Inc Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US20210299187A1 (en) * 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014391A1 (en) * 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019203965A1 (en) * 2018-04-17 2019-10-24 The Johns Hopkins University Recombinant therapeutic interventions for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021163602A1 *

Also Published As

Publication number Publication date
CN115443143A (en) 2022-12-06
WO2021163602A1 (en) 2021-08-19
CA3167223A1 (en) 2021-08-19
EP4103208A1 (en) 2022-12-21
JP2023514553A (en) 2023-04-06
AU2021220986A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
EP3781184A4 (en) Recombinant therapeutic interventions for cancer
EP3915583A4 (en) Combined pharmaceutical composition for treating tumor
EP4081248A4 (en) Therapy for the treatment of cancer
EP4010081A4 (en) Combination therapy for treatment of cancer
EP3970745A4 (en) Pharmaceutical composition for treating tumor
GB202301902D0 (en) Combination therapy for cancer
EP4090369A4 (en) Pericyte-sparing therapy
EP4103208A4 (en) Recombinant therapeutic interventions for cancer
EP4316341A4 (en) Power-providing device for medical device
EP4190340A4 (en) Therapeutic drug or diagnostic drug for cancer
EP3981473A4 (en) Therapeutic agent for cancer
EP3949990A4 (en) Medicament for treating cancer
EP3969027A4 (en) Polypeptides for treatment of cancer
EP4013440A4 (en) Therapeutic peptides
EP3897669A4 (en) Methods and compositions related to therapeutic peptides for cancer therapy
EP3966567A4 (en) Therapeutic peptides
EP4186520A4 (en) Cancer therapeutic agent
EP4054628A4 (en) Combination therapy for cancer
EP4135849A4 (en) Miv-818/lenvatinib combination therapy for liver cancer
EP3858321B8 (en) Moulding for neuromuscular therapy
AU2022297426A1 (en) Therapeutic compounds
AU2023901714A0 (en) Combination cancer therapy
EP3946629A4 (en) Therapeutic targets for oncogenic kras-dependent cancers
AU2023903316A0 (en) Novel cancer therapy
AU2022903054A0 (en) Novel cancer therapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

A4 Supplementary search report drawn up and despatched

Effective date: 20240410

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/74 20060101ALI20240404BHEP

Ipc: A61P 35/00 20060101ALI20240404BHEP

Ipc: A61K 39/00 20060101ALI20240404BHEP

Ipc: C12N 15/70 20060101ALI20240404BHEP

Ipc: A61K 39/39 20060101ALI20240404BHEP

Ipc: A61K 39/04 20060101ALI20240404BHEP

Ipc: A61K 35/74 20150101AFI20240404BHEP